Houston Biotech Secured $120 Million for Implants
Duracyte has raised funds to develop subcutaneous engineered cell implants that secrete biologics.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Would you trust a long-term under-the-skin implant over traditional repeated injection treatments for chronic conditions?
Houston-based startup Duracyte has secured $120 million in non-dilutive funding to advance its engineered human cell technology. The company intends to use the capital to move its subcutaneous implant technology into clinical testing for cancer patients.
Why it matters
This technology aims to eliminate the need for recurring injections and infusions by providing a consistent delivery method for therapeutic biologics. By enabling controlled, long-term drug secretion, the implants seek to improve treatment consistency for complex medical conditions.
The implants feature engineered human cells capable of secreting biologics continuously for up to one year after being placed under the skin. Duracyte plans to test the platform using the checkpoint inhibitor ipilimumab for patients with peritoneal cancer.
The players
Duracyte
Duracyte is a Houston-based biotechnology company specializing in the development of engineered cell-based subcutaneous implants.
The details
The firm is creating a system where bio-engineered cells act as internal drug factories, allowing for sustained therapy without external intervention. These devices are designed to stay functional for a full year, significantly extending the duration between required medical dosing sessions.
Timeline
Duracyte expects to launch its inaugural clinical trial during the first half of 2027.
The Tech Race
This development represents a shift toward localized, sustained-release biologics that challenge the dominance of traditional systemic infusion therapies. By moving drug production inside the body, the company competes with emerging gene and cell-based medicine platforms for a dominant role in long-term oncology care.
Patients may eventually see a reduction in the frequency of clinic visits required for biologics if the subcutaneous technology replaces recurring infusions. The success of these trials could eventually simplify treatment plans for individuals managing chronic, long-term conditions.
The takeaway
Advancements in cell-based delivery systems highlight the transition toward more convenient, autonomous therapeutic options for oncology. Patients and families should monitor future trial results to understand how these long-acting implants could eventually change standard treatment timelines.
What happens next
Duracyte plans to begin its first clinical trial enrolling patients with peritoneal cancer in the first half of 2027.
Further reading
For more information on the latest innovations in this field, visit our Biotech section.
Source note: This article includes information reported by BioCentury.
Live Poll
Would you trust a long-term under-the-skin implant over traditional repeated injection treatments for chronic conditions?
